Login / Signup

A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and β-catenin nuclear accumulation.

Xi ChenXin LiuQian-Hui LiBing-Feng LuBu-Min XieYu-Meng JiYang Zhao
Published in: Journal of experimental & clinical cancer research : CR (2023)
ASO targeting SNORD14E can be an effective treatment for EC.
Keyphrases
  • endometrial cancer
  • cancer therapy
  • poor prognosis
  • cell proliferation
  • binding protein
  • drug delivery
  • long non coding rna
  • replacement therapy
  • smoking cessation